Welcome to our dedicated page for KALA BIO news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on KALA BIO stock.
KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
Kala Pharmaceuticals (NASDAQ: KALA) will participate in two investor conferences in January 2021. Mark Iwicki, Chairman and CEO, is set to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 9:10 a.m. ET. He will also have a pre-recorded fireside chat at the H.C. Wainwright BioConnect Conference, available on the Kala website starting January 11, 2021, at 6:00 a.m. ET. Kala focuses on innovative therapies for eye diseases, with products like EYSUVIS™ and INVELTYS®.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has granted non-statutory stock options to 46 new employees, totaling 233,500 shares, as inducement awards outside its 2017 Equity Incentive Plan. The options were issued on December 15, 2020, with an exercise price of $7.63, corresponding to the closing stock price on that date. Vesting occurs over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter. This grant aligns with NASDAQ Listing Rule 5635(c)(4) and supports the firm's commitment to attract talent in the biopharmaceutical sector focused on ocular therapies.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has granted non-statutory stock options to four new employees as inducement awards outside its 2017 Equity Incentive Plan, following NASDAQ Listing Rule 5635(c)(4). A total of 34,500 stock options were granted on November 13, 2020, with an exercise price of $7.42 per share, matching the closing stock price on that date. The options vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments, contingent on continued employment.
Kala Pharmaceuticals (NASDAQ:KALA) is preparing to launch EYSUVIS, an ophthalmic suspension for treating dry eye disease, with plans to begin shipping by mid-December. The company has expanded its sales force, targeting 125 representatives by 2021. EYSUVIS, approved by the FDA on October 26, 2020, will retail at a wholesale acquisition cost of $465 per 10 mL bottle. With $159.1 million in cash as of September 30, 2020, Kala anticipates its financial position will support operations at least until Q3 2022.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will present at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 2:05 p.m. GMT. CEO Mark Iwicki will participate in a fireside chat, highlighting the company's innovative therapies for eye diseases. Notable products include EYSUVIS™, approved in October 2020 for treating dry eye disease, and INVELTYS®, launched in January 2019 for post-operative inflammation.
Access the live webcast and recordings on the Kala website under the 'Investors' section.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced it will report its third quarter 2020 financial results on November 5, 2020. The conference call will take place at 8:00 a.m. ET, where management will discuss financial results and business updates. Kala is noted for its AMPPLIFY® Drug Delivery Technology, which led to the recent approval of EYSUVIS™ for dry eye disease and the launch of INVELTYS® for post-operative inflammation. Investors can access the call via dial-in or the company's website.
Kala Pharmaceuticals (NASDAQ: KALA) announced FDA approval for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, marking it as the first prescription therapy for short-term treatment of dry eye disease. This innovative therapy utilizes Kala's AMPPLIFY Drug Delivery Technology to enhance the drug's effectiveness. EYSUVIS is set to launch in the U.S. by year-end, aiming to address the significant unmet needs of approximately 80% of patients experiencing episodic dry eye flares. The FDA's approval is based on substantial clinical trial results demonstrating rapid relief from symptoms.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the grant of non-statutory stock options to four new employees, totaling 42,000 shares. These options, with an exercise price of $8.01 per share, were provided as inducement awards outside the 2017 Equity Incentive Plan, in line with NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, the options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. Kala focuses on innovative therapies for eye diseases, including its product INVELTYS and the investigational EYSUVIS, for which a New Drug Application is under FDA review with a target action date of October 30, 2020.